509 related articles for article (PubMed ID: 30605918)
1. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
Paciullo F; Momi S; Gresele P
Thromb Haemost; 2019 Mar; 119(3):359-367. PubMed ID: 30605918
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
Bittner V
Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
[No Abstract] [Full Text] [Related]
3. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
Chamberlain AM; Gong Y; Shaw KM; Bian J; Song WL; Linton MF; Fonseca V; Price-Haywood E; Guhl E; King JB; Shah RU; Puro J; Shenkman E; Pawloski PA; Margolis KL; Hernandez AF; Cooper-DeHoff RM
J Am Heart Assoc; 2019 May; 8(9):e011246. PubMed ID: 31020929
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
5. The PCSK9 revolution: Current status, controversies, and future directions.
Warden BA; Fazio S; Shapiro MD
Trends Cardiovasc Med; 2020 Apr; 30(3):179-185. PubMed ID: 31151804
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
7. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M
Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 inhibition 2018: riding a new wave of coronary prevention.
Ward NC; Page MM; Watts GF
Clin Sci (Lond); 2019 Jan; 133(2):205-224. PubMed ID: 30670671
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.
Handelsman Y; Lepor NE
J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29934421
[No Abstract] [Full Text] [Related]
10. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up.
Barale C; Bonomo K; Frascaroli C; Morotti A; Guerrasio A; Cavalot F; Russo I
Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):282-291. PubMed ID: 31653513
[TBL] [Abstract][Full Text] [Related]
11. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD; Aday AW; Rose LM; Ridker PM
Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
[TBL] [Abstract][Full Text] [Related]
12. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Nabavi SM; Lavie CJ; Banach M;
Prog Cardiovasc Dis; 2021; 67():65-74. PubMed ID: 33383060
[TBL] [Abstract][Full Text] [Related]
13. Lipid management in ACS: Should we go lower faster?
Gencer B; Mach F
Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
[TBL] [Abstract][Full Text] [Related]
14. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
16. Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?
Noto D; Giammanco A; Barbagallo CM; Cefalù AB; Averna MR
Cardiovasc Res; 2018 Oct; 114(12):1595-1604. PubMed ID: 29931148
[TBL] [Abstract][Full Text] [Related]
17. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors.
Alali RA
Rev Cardiovasc Med; 2019 Mar; 20(1):1-8. PubMed ID: 31184090
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibitors: clinical evidence and implementation.
Sabatine MS
Nat Rev Cardiol; 2019 Mar; 16(3):155-165. PubMed ID: 30420622
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
